Share 'Gottlieb Targets Drug Development Costs, Clinical Development Efficiencies'
Posted 11 September 2017 By Zachary Brennanwww.raps.org/uploadedImages/Site_Setup/Regulatory_Focus/News/2017/07/Gottlieb%20converge.jpg" alt="placeholder+image" />
FDA commissioner Scott Gottlieb on Monday explained to attendees of RAPS’ Regulatory Convergence conference some steps FDA is taking to make the clinical end of drug development more efficient and effective.
Opening with a discussio…
You can share this blog post in two ways…
Share this link:
Send it with your computer's email program: Email this